Signal Analysts put Spravato global sales at $2 billion in 2025

Summary

The Psychedelics and Healing Initiative points to Spravato as a commercial precedent for the field. Spravato is Johnson and Johnson's intranasal therapy based on esketamine, a form of ketamine, and the Initiative calls it a great success for the company. The drug had earlier received FDA breakthrough therapy designation, the same status now held by eight psychedelic candidates. Analysts cited by the Initiative expect its worldwide sales to reach 2 billion dollars in 2025. GWI uses the figure to show that a regulated, reimbursable medicine in this area can achieve large commercial scale. The analysts are not named, so the estimate should be read as an industry projection.